Xi'an Mental Health Center, School of Medicine, Xi'an Jiaotong University, Xi'an, China.
College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, China.
Pharm Biol. 2021 Dec;59(1):222-231. doi: 10.1080/13880209.2021.1878236.
Rosmarinic acid (RosA), a natural poly-phenolic compound isolated from a variety of Labiatae herbs, has been reported to have a range of biological effects.
To investigate the cardioprotective effects of RosA against myocardial ischaemia/reperfusion (I/R) injury.
Male C57BL/6J mice were given RosA (100 mg/kg) via intragastric administration. After 1 week of administration, the mice were subjected to 30 min/24 h myocardial I/R injury. The mice were randomly subdivided into 4 groups: Vehicle, RosA, Vehicle + I/R, and RosA + I/R. Infarct size (IS), cardiac function (including EF, FS), histopathology, serum enzyme activities, ROS changes, cis aconitase (ACO) activity, and specific mRNA and protein levels were assessed . HL-1 cells were pre-treated with or without RosA (50 μM), followed by stimulation with 9 h/6 h of oxygen and glucose deprivation/re-oxygenation (OGD/R). The cells were randomly subdivided into 4 groups: Vehicle, RosA, Vehicle + OGD/R, and RosA + OGD/R. Lactate dehydrogenase (LDH) levels, ACO activity, ROS changes and protein levels were measured .
Treatment with RosA reduced the following indicators ( < 0.05): (1) IS (14.5%); (2) EF (-23.4%) and FS (-18.4%); (3) the myocardial injury enzymes CK-MB (20.8 ng/mL) and cTnI (7.7 ng/mL); (4) DHE-ROS: (94.1%); (5) ACO activity (-2.1 mU/mg protein); (6) mRNA level (122.9%); and (7) OGDH protein level (69.9%). Moreover, treatment with RosA attenuated the following indicators ( < 0.05): (1) LDH level (191 U/L); (2) DHE-ROS: (165.2%); (3) ACO activity (-3.2 mU/mg protein); (4) mRNA level (70.0%); and (5) OGDH (110.1%), p-IκB-a (56.8%), and p-NF-κB (57.7%) protein levels.
RosA has the potential to treat myocardial I/R injury with potential application in the clinic.
迷迭香酸(RosA)是一种从多种唇形科草药中分离出来的天然多酚化合物,已被报道具有多种生物学效应。
研究迷迭香酸(RosA)对心肌缺血/再灌注(I/R)损伤的心脏保护作用。
雄性 C57BL/6J 小鼠经灌胃给予 RosA(100mg/kg)。给药 1 周后,小鼠进行 30 分钟/24 小时心肌 I/R 损伤。将小鼠随机分为 4 组:载体组、RosA 组、载体+I/R 组和 RosA+I/R 组。评估梗死面积(IS)、心脏功能(包括 EF、FS)、组织病理学、血清酶活性、ROS 变化、顺乌头酸酶(ACO)活性以及特定的 mRNA 和蛋白水平。HL-1 细胞用或不用 RosA(50μM)预处理,然后进行 9 小时/6 小时的氧和葡萄糖剥夺/再氧合(OGD/R)刺激。将细胞随机分为 4 组:载体组、RosA 组、载体+OGD/R 组和 RosA+OGD/R 组。测量乳酸脱氢酶(LDH)水平、ACO 活性、ROS 变化和蛋白水平。
RosA 治疗降低了以下指标 ( < 0.05):(1)IS(14.5%);(2)EF(-23.4%)和 FS(-18.4%);(3)心肌损伤酶 CK-MB(20.8ng/mL)和 cTnI(7.7ng/mL);(4)DHE-ROS:(94.1%);(5)ACO 活性(-2.1mU/mg 蛋白);(6)mRNA 水平(122.9%);和(7)OGDH 蛋白水平(69.9%)。此外,RosA 治疗降低了以下指标 ( < 0.05):(1)LDH 水平(191U/L);(2)DHE-ROS:(165.2%);(3)ACO 活性(-3.2mU/mg 蛋白);(4)mRNA 水平(70.0%);和(5)OGDH(110.1%)、p-IκB-a(56.8%)和 p-NF-κB(57.7%)蛋白水平。
RosA 具有治疗心肌 I/R 损伤的潜力,有望在临床上应用。